A L Pappy1, A Savinkina2, C Bicknese1, S Neill3, N M Oyesiku4,5, A G Ioachimescu6,7. 1. Emory University School of Medicine, Atlanta, GA, USA. 2. Emory Rollins School of Public Health, Atlanta, GA, USA. 3. Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA. 4. Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 1364 Clifton Road NE, Atlanta, GA, 30322, USA. 5. Department of Neurosurgery, Emory University School of Medicine, 1365 B Clifton Rd NE, Atlanta, GA, USA. 6. Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, 1364 Clifton Road NE, Atlanta, GA, 30322, USA. aioachi@emory.edu. 7. Department of Neurosurgery, Emory University School of Medicine, 1365 B Clifton Rd NE, Atlanta, GA, USA. aioachi@emory.edu.
Abstract
BACKGROUND: Personalized postoperative management of patients with pituitary adenomas requires an early risk stratification system. METHODS: We reviewed 501 cases operated between 10/27/2011 and 5/5/2016 by a single neurosurgeon. We determined biochemical remission and tumor resection at 3 months, and biochemical recurrence, tumor recurrence, radiation and reoperation during follow-up. We considered age, gender, tumor diameter, cavernous sinus invasion (CSI) by MRI, diagnostic category (clinical, biochemical and immunohistochemical), and proliferation markers in a Cox proportional hazards model. We built predictive models with the significant parameters and used Kaplan-Meier survival curves for time-dependent analyses. RESULTS: The 501 cases comprised 141 functional and 360 nonfunctional adenomas. Tumor diameter, CSI, and ki-67 index predicted long-term events. Model 1 (CSI, diameter ≥ 2.9 cm and ki-67 > 3%) identified 18 (3.6%) adenomas and predicted persistent hypersecretory syndrome and residual tumor with 98.7% specificity (OR 8.6; CI 3.0-24.7). Model 2 (ki-67 > 3% and CSI) identified 48 (9.6%) adenomas and had 93.1% specificity (OR 3.3; CI 1.8-6.0). Model 3 (ki-67 > 3%, mitoses and p53, former "atypical" adenoma) identified 26 (5.2%) adenomas and had 96.0% specificity (OR 2.3; CI 1.0-5.0). Model 1 best predicted the long-term event-free survival and was strengthened when Knosp 3-4 CSI grades were used. Model 2 better identified the smaller adenomas at risk. Among the WHO 2017 special PA subtypes, patients with silent corticotroph adenoma had a lower event-free survival than ACTH-negative nonfunctional adenomas. CONCLUSION: Use of CSI, ki-67 and tumor diameter in prediction models facilitates tailored surveillance and management of patients with pituitary adenomas.
BACKGROUND: Personalized postoperative management of patients with pituitary adenomas requires an early risk stratification system. METHODS: We reviewed 501 cases operated between 10/27/2011 and 5/5/2016 by a single neurosurgeon. We determined biochemical remission and tumor resection at 3 months, and biochemical recurrence, tumor recurrence, radiation and reoperation during follow-up. We considered age, gender, tumor diameter, cavernous sinus invasion (CSI) by MRI, diagnostic category (clinical, biochemical and immunohistochemical), and proliferation markers in a Cox proportional hazards model. We built predictive models with the significant parameters and used Kaplan-Meier survival curves for time-dependent analyses. RESULTS: The 501 cases comprised 141 functional and 360 nonfunctional adenomas. Tumor diameter, CSI, and ki-67 index predicted long-term events. Model 1 (CSI, diameter ≥ 2.9 cm and ki-67 > 3%) identified 18 (3.6%) adenomas and predicted persistent hypersecretory syndrome and residual tumor with 98.7% specificity (OR 8.6; CI 3.0-24.7). Model 2 (ki-67 > 3% and CSI) identified 48 (9.6%) adenomas and had 93.1% specificity (OR 3.3; CI 1.8-6.0). Model 3 (ki-67 > 3%, mitoses and p53, former "atypical" adenoma) identified 26 (5.2%) adenomas and had 96.0% specificity (OR 2.3; CI 1.0-5.0). Model 1 best predicted the long-term event-free survival and was strengthened when Knosp 3-4 CSI grades were used. Model 2 better identified the smaller adenomas at risk. Among the WHO 2017 special PA subtypes, patients with silent corticotroph adenoma had a lower event-free survival than ACTH-negative nonfunctional adenomas. CONCLUSION: Use of CSI, ki-67 and tumor diameter in prediction models facilitates tailored surveillance and management of patients with pituitary adenomas.
Authors: J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young Journal: Neurosurgery Date: 2000-09 Impact factor: 4.654
Authors: M L Jaffrain-Rea; D Di Stefano; G Minniti; V Esposito; A Bultrini; E Ferretti; A Santoro; L Faticanti Scucchi; A Gulino; G Cantore Journal: Endocr Relat Cancer Date: 2002-06 Impact factor: 5.678
Authors: Venkatram Subramanian; Rachel Su Min Lee; Simon Howell; Samuel Gregson; Ian M Lahart; Kalpana Kaushal; Joseph M Pappachan Journal: Endocrine Date: 2021-04-06 Impact factor: 3.633
Authors: Alberto Acitores Cancela; Víctor Rodríguez Berrocal; Héctor Pian; Juan Salvador Martínez San Millán; Juan José Díez; Pedro Iglesias Journal: Hormones (Athens) Date: 2021-06-19 Impact factor: 2.885